单位:[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurol, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属协和医院[2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Nucl Med, Wuhan, Hubei, Peoples R China核医学科华中科技大学同济医学院附属同济医院[3]Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurol, New York, NY 10029 USA[4]Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA
Blood-brain barrier (BBB) disruption plays a critical role in brain injury induced by cerebral ischemia, and preserving BBB integrity during ischemia could alleviate cerebral injury. We examined the role of miR-130a in ischemic BBB disruption by using models of rat middle cerebral artery occlusion and cell oxygen-glucose deprivation. We found that ischemia significantly increased microRNA-130a (miR-130a) level and that miR-130a was predominantly from brain microvascular endothelial cells. Antagomir-130a, an antagonist of miR-130a, could attenuate brain edema, lower BBB permeability, reduce infarct volume, and improve neurologic function. MiR-130a overexpression induced by miR-130a mimic increased monolayer permeability, and intercellular inhibition of miR-130a by a miR-130a inhibitor suppressed oxygen-glucose deprivation-induced increase in monolayer permeability. Moreover, dual luciferase reporter system showed that Homeobox A5 was the direct target of miR-130a. MiR-130a, by inhibiting Homeobox A5 expression, could down-regulate occludin, thereby increasing BBB permeability. Our results suggested that miR-130a might be implicated in ischemia-induced BBB dysfunction and serve as a target for the treatment of ischemic stroke.
基金:
National Natural Science Foundation of China [81301001, 81571119, 81371311, 81571139, 81671147, 81301002, 81400969, 81400970, 81601027]; National Key Research and Development Program of China [2016YFC1300600]; National Research Foundation for the Doctoral Program of Higher Education of China [20120142110068]; New Century Excellent Talents in University [NCET-10-0406]